Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 5, 1997, Pages 365-369

  Kaputlu, Irfan ^a   Şadan, Gülay ^a   Karayalçin, Binnur ^a   Boz, Adil ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

blood pressure; cyclosporine A; nephrotoxicity; pentoxifylline

Indexed keywords

CYCLOSPORIN; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG INDUCED DISEASE; ERYTHROCYTE DEFORMABILITY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0030995046     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01203.x     Document Type: Article

References (56)

1. Myers BD. Cyclosporine nephrotoxicity. Kidney Int. 1986; 30: 964-76.
2. Schachter M. Editorial review. Cyclosporine A and hypertension. J. Hypertens. 1988; 6: 511-16.
3. Loughran TP, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br. J. Haematol 1985; 59: 547-53.
4. Berg KJ, Forre O, Bjerkhoel F et al. Side effects of cyclosporine A treatment in patients with rheumatoid arthritis. Kidney Int. 1986; 29: 1180-7.
5. Palestine AG, Howard AA, Balow JE et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N. Engl. J. Med. 1986; 314: 1293-8.
6. Monaco DO, Wait RB, Friedman AL, Kahng KU. Effects of chronic cyclosporine therapy on renal vascular reactivity in the isolated perfused rabbit kidney. Transplant. Proc. 1988; 20: 578-83.
7. Nahman NS, Cosio FG, Mahan JD, Henry ML, Ferguson RM. Cyclosporine nephrotoxicity in spontaneously hypertensive rats. Transplantation 1988; 45: 768-72.
8. Gerkens FJ. Cyclosporine treatment of normal rats produces a rise in blood pressure and decreased renal vascular responses to nerve stimulation, vasoconstrictors and endothelium-dependent dilators. J. Pharmacol. Exp. Ther. 1989; 250: 1105-12.
9. Murray BR, Palmer MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 1985; 28: 767-74.
10. Whitworth JA, Mills EH, Coghlan JP et al. The haemodynamic effects of cyclosporine A in sheep. Clin. Exp. Pharmacol. Physiol. 1987; 14: 573-80.
11. Rossi NF, Churchill PC, McDonald FD, Ellis VR. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat J. Pharmacol. Exp. Ther. 1989; 250: 896-901.
12. Rego A, Vargas R, Cathapermal S, Kuwahara M, Foegh ML, Ramwell PW. Systemic vascular effects of cyclosporin A treatment in normotensive rats. J. Pharmacol. Exp. Ther. 1991; 259: 905-15.
13. Urakaze M, Hamazaki T, Kashiwabara H et al. Favorable effects of fish oil concentrate on risk factors for thrombosis in renal allograft recipients. Nephron 1989; 53: 102-9.
14. Schul NH, Bilo HJG, Popp-Snijders C, Goedhart PT, Wilmink JM. Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal transplant recipients: Effect of intervention with fish oil and corn oil. Scand. J. Clin. Lab. Invest. 1993; 53: 499-506.
15. Reinhart WH. Binding of cyclosporine by erythrocytes: Influence on cell shape and deformability. Eur. J. Clin. Invest. 1993; 23: 177-81.
16. Başkurt OK, Şentürk ÜK, Dayan N et al. Cyclosporin A affects red blood cell deformability in vivo but not in vitro in guinea pig. J. Pharmacol. Exp. Ther. 1995; 274: 1438-42.
17. Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DR. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob. Agents Chemother. 1990; 34: 241-1.
18. Bianco JA, Almgren J. Kern DL et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991; 51: 925-7.
19. Harada H, Ishizaka A, Yonemaru M et al. The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am. Rev. Resp. Dis. 1989; 140: 974-80.
20. Zabel P, Schönharting MM, Volter DT, Schade UF. Oxpentifylline in endotoxemia. Lancet 1989; ii: 1474-7.
21. Berens KL, Langston JD, Wasan KM, Luke DR. Influence of pentoxifylline and related analogues in endotoxemic renal failure. Circ. Shock 1991; 34: 344-8.
22. Vadiei K, Brunner LJ, Luke DR. Effects of pentoxifylline in experimental acute renal failure. Kidney Int. 1989; 36: 466-70.
23. Takayanagi S, Ogawa Y. Effects of pentoxifylline on flap survival. Plastic Reconstruct. Surg. 1980; 65: 763-7.
24. Brunner LJ, Vadiei K, Iyer LV, Luke DR. Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. Renal Failure 1989; II: 97-104.
25. Berkenboom G, Unger P, Goldman M, Fang ZY, Fontaine J. Prevention of cyclosporine A-induced vascular toxicity by pentoxifylline. J. Cardiovasc. Pharmacol. 1991; 18: 761-8.
26. Bennett WM, Elzinga LW, Porter GA, Rosen S . The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity. Transplantation 1992; 54: 1118-20.
27. 2) by pentoxifylline from human vascular tissue. Drug Res. 1982; 32: 1315-18.
28. Berkenboom G, Fang ZY, Unger P, Goldman M, Fontaine J. Endothelium-dependent effects of pentoxifylline in rat aorta. Eur. J. Pharmacol. 1991; 193: 81-6.
29. Luke DR, Rocci ML Jr. Determination of pentoxifylline and a major metabolite 3,7-dimethyl-1-(5′-hydroxyhexyl)xanthine, by high-performance liquid chromatography. J. Chromatogr. 1986; 374: 191-5.
30. 99mTc]-DTPA (Stannous). Am. J. Roentgenol. 1982; 138: 565-70.
31. McAffee JG, Thomas FD, Subramanian G, Lyons B, Roskopf M. Detection of diffuse glomerular lesions in rats. 1. Comparison of conventional radioactive agents J. Nuclear Med. 1986; 27: 502-12.
32. McAffee JG, Kopecky RT, Thomas FD, Hellwig B, Roskopf M. Comparison of different radioactive agents for the detection of renovascular hypertension with captopril in a rat model. J. Nuclear Med. 1988; 29: 509-15.
33. Myers BD, Ross JC, Newton LD, Luetscher JA, Perlroth MG. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984; 311: 699-705.
34. Mihatsch MJ, Ryfee B, Hermle M, Brunner EP, Thiel G. Morphology of cyclosporine nephrotoxicity in the rat. Clin. Nephrol. 1986; 25 (Suppl. 1): S2-8.
35. Jackson NM, Hsu CH, Visscher GE, Venkatachalam MA, Humes HD. Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. J. Pharmacol. Exp. Ther. 1987; 242: 749-56.
36. Xue H, Bukoski RD, McCaron DA, Bennett VM. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 1987; 43: 715-18.
37. Cairns HS, Fairbanks LD, Westwick J, Neild GH. Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit. Br. J. Pharmacol. 1989; 98: 463-8.
38. 2 synthesis induced by cyclosporine A. Am. J. Physiol. 1986; 251: F581-7.
39. Brown Z, Neild GH, Lewis GP. Mechanism of inhibition of prostacyclin synthesis by cyclosporine in cultured human umbilical vein endothelial cells. Transplant. Proc. 1988; 20: 654-7.
40. Voss BL, Hamilton KK, Scott Samara EN, McKee PA. Cyclosporine suppression of endothelial prostacyclin generation. Transplantation 1988; 45: 793-6.
41. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. The role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990; 37: 1487-91.
42. Nakahama H. Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial cell line, LLC-PK1 cells. Eur. J. Pharmacol. 1990; 180: 191-2.
43. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J. Clin, Invest. 1991; 88: 310-14.
44. Rego A, Vargas R, Wroblewska B, Foegh ML, Ramwell PW. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J. Pharmacol. Exp. Ther. 1990; 252: 165-70.
45. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab. Invest. 1986; 55: 455-62.
46. Poggesi L, Boddi M, Scanti L, Masotti G. Pentoxifylline and prostaglandins. Ricerca Clin. Lab. 1988; 18 (Suppl. 2): 37-46.
47. Carrier M, Perrault LP, Tronc F. Stewart DJ, Pelletier CL. Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction. Ann. Thoracic Surg. 1993; 55: 490-2.
48. Hoeffner U, Aarhus LL, Katusic ZS, Vanhoutte PM. Pharmacology of pentoxifylline in isolated canine arteries and veins. J. Cardiovasc. Pharmacol. 1989; 14: 899-907.
49. Kaputlu İ, Şadan G. Pentoxifylline induced vasodilatation is not endothelium-dependent in rabbit aorta. J. Basic Clin. Physiol. Pharmacol. 1994; 5: 295-304.
50. Crowell RE, Chick TW, Reed WP. Pentoxifylline relaxes isolated pulmonary arteries after preconstriction with norepinephrine. Respiration 1990; 57: 45-50.
51. Ward A, Clissold S. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97.
52. Dauber IM, Lesnefsky EJ, Ashmore RC et al. Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J. Pharmacol. Exp.Ther. 1992; 260: 1250-6.
53. Dieperink H, Leyssac PP, Starklint K, Jorgensen A, Kemp E. Antagonist capacities of nifedipine, captopril, phenoxybenzamine, prostacyclin and indomethacin on cyclosporine A-induced impairment of rat renal function. Eur. J. Clin. Invest. 1986; 16: 540-8.
54. Bunke M, Wilder L. Effect of verapamil on glomerular filtration rate and glomerular prostaglandin production during cyclosporine administration. Transplantation 1988; 46: 919-21.
55. Ellory JC, Culliford SJ, Horwitz ER, Mojiminiyi FBO, Stuart J. Oxpentifylline-induced inhibition of calcium entry into human erythrocytes. Clin. Hemorheol. 1994; 14: 545-55.
56. Bianco JA, Appelbaum FR, Nemunaitis J et al. Phase 1-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205-11.